3+、CD4+、CD8+)及NK細(xì)胞活性的變化,考察毒副反應(yīng)情況和生活質(zhì)量的改善情況。結(jié)果 治療后,對(duì)照組和治療組的總有效率分別為61.90%、85.71%,兩組總有效率比較差異具有統(tǒng)計(jì)學(xué)意義(P<0.05)。治療后,治療組CD3+、CD4+和NK細(xì)胞活性明顯上升,CD8+活性降低,同組治療前后差異具有統(tǒng)計(jì)學(xué)意義(P<0.05);且治療組這些觀察指標(biāo)的改善程度明顯優(yōu)于對(duì)照組,兩組比較差異具有統(tǒng)計(jì)學(xué)意義(P<0.05)。治療后,治療組骨髓抑制、便秘發(fā)生率分別為2.38%、4.76%,均低于對(duì)照組(P<0.05),其惡心/嘔吐、肝腎功能異常、腹瀉、黏膜炎發(fā)生率均略低于對(duì)照組,但差異無統(tǒng)計(jì)學(xué)意義。治療后,治療組KPS評(píng)分明顯升高,同組治療前后比較差異具有統(tǒng)計(jì)學(xué)意義(P<0.05);且治療組KPS評(píng)分的上升幅度明顯高于對(duì)照組,兩組比較差異具有統(tǒng)計(jì)學(xué)意義(P<0.05)。結(jié)論 養(yǎng)正消積膠囊聯(lián)合FOLFIRI化療方案治療結(jié)直腸癌具有較好的臨床療效,強(qiáng)化患者免疫抵抗力,改善生活質(zhì)量,提高治療的安全性,具有一定的臨床推廣應(yīng)用價(jià)值。;ObjectiveTo observe the clinical efficacy of Yangzheng Xiaoji Capsules combined with FOLFIRI scheme in treatment of colorectal cancer. Methods Patients (84 cases) with colorectal cancer who received surgical treatment in Shaanxi Provincial Tumor Hospital from April 2013 to March 2015 were numbered according to the order of registration and admission, and divided into the control group and treatment group according to the random number table method, and each group had 42 cases. The patients in the control group were treated by FOLFIRI chemotherapy scheme. The patients in the treatment group were po administered with Yangzheng Xiaoji Capsules, 4 capsules/time, three times daily. The patients in two groups were treated for two courses. After treatment, the clinical efficacies were evaluated, and the changes of T lymphocyte subsets (CD3+, CD4+, and CD8+) and NK cell activity were compared between the two groups. In the same time, incidence of adverse reactions and improvement of quality of life between two groups were analyzed. Results After treatment, the clinical efficacies in the control and treatment groups were 61.90% and 85.71%, respectively, and there was difference between two groups (P < 0.05). After treatment, CD3+, CD4+ and NK activity of the treatment group were significantly increased, while CD8+ activity was decrease, and the difference was statistically significant in the same group (P < 0.05). And those immune function indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the incidence rates of myelosuppression and constipation in the treatment group were 2.38% and 4.76%, and lower than those in the control group (P < 0.05). The incidence rates of nausea/vomiting, hepatorenal dysfunction, diarrhea, and mucosal inflammation were slightly lower than those in the control group, but the differences were not statistically significant. After treatment, KPS score in the treatment group were significantly increased, and the difference was statistically significant in the same group (P < 0.05). After treatment, the rise ranges in the treatment group higher than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Yangzheng Xiaoji Capsules combined with FOLFIRI scheme has clinical curative effect in the treatment of colorectal cancer, can strengthen immunity, improve the quality of life of patients, is less adverse reactions, which has a certain clinical application value."/>